OncoMatch/Clinical Trials/NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Is NCT05920356 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Sotorasib and Pembrolizumab for non-small cell lung cancer (nsclc).
Treatment: Sotorasib · Pembrolizumab — The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C
KRAS p. G12C mutation
Required: PD-L1 (CD274) negative for expression (negative)
negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS G12C inhibitor
Prior therapy with a KRAS G12C inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sansum Clinic · Santa Barbara, California
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center · Newark, Delaware
- University of Illinois Chicago · Chicago, Illinois
- Illinois Cancer Specialists · Niles, Illinois
- Norton Cancer Institute - Brownsboro · Louisville, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify